|374.14||-0.1000||-0.03%||Vol 164.62K||1Y Perf 19.52%|
|Aug 11th, 2022 16:00 DELAYED|
|- -||- -%|
|Target Price||402.73||Analyst Rating||Strong Buy 1.25|
|Potential %||7.64||Finscreener Ranking||★★★+ 51.37|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||★★★+ 52.76|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||★★ 45.17|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Price Range Ratio 52W %||90.06||Earnings Rating||Strong Buy|
|Market Cap||20.60B||Earnings Date||28th Jul 2022|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|5 Years||1 788.64%|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-4.77|
|EPS Growth Next 5 Years %||3.20|
|Avg. Weekly Volume||170.58K|
|Avg. Monthly Volume||251.47K|
|Avg. Quarterly Volume||290.91K|
argenx SE (NASDAQ: ARGX) stock closed at 374.14 per share at the end of the most recent trading day (a -0.03% change compared to the prior day closing price) with a volume of 164.62K shares and market capitalization of 20.60B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 188 people. argenx SE CEO is Tim Van Hauwermeiren.
The one-year performance of argenx SE stock is 19.52%, while year-to-date (YTD) performance is 6.84%. ARGX stock has a five-year performance of 1788.64%. Its 52-week range is between 249.5 and 387.89, which gives ARGX stock a 52-week price range ratio of 90.06%
argenx SE currently has a PE ratio of -31.60, a price-to-book (PB) ratio of 7.81, a price-to-sale (PS) ratio of 393.03, a price to cashflow ratio of 57.40, a PEG ratio of 2.32, a ROA of -17.83%, a ROC of -19.41% and a ROE of -19.95%. The company’s profit margin is -82.10%, its EBITDA margin is -71.20%, and its revenue ttm is $50.29 Million , which makes it $0.93 revenue per share.
Of the last four earnings reports from argenx SE, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-4.77 for the next earnings report. argenx SE’s next earnings report date is -.
The consensus rating of Wall Street analysts for argenx SE is Strong Buy (1.25), with a target price of $402.73, which is +7.64% compared to the current price. The earnings rating for argenx SE stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
argenx SE has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
argenx SE has a Buy technical analysis rating based on Technical Indicators (ADX : 16.33, ATR14 : 11.89, CCI20 : 119.21, Chaikin Money Flow : -0.10, MACD : 4.28, Money Flow Index : 53.45, ROC : 2.92, RSI : 39.79, STOCH (14,3) : 60.79, STOCH RSI : 1.00, UO : 54.20, Williams %R : -39.21), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of argenx SE in the last 12-months were:
Fri, 29 Jul 2022 12:38 GMT Morgan Stanley Believes Argenx Se (ARGX) Still Has Room to Grow- TipRanks. All rights reserved.
Mon, 27 Jun 2022 10:15 GMT H.C. Wainwright Believes Argenx Se (ARGX) Still Has Room to Grow- TipRanks. All rights reserved.
Wed, 25 May 2022 02:36 GMT Argenx Se (ARGX) Initiated with a Buy at SVB Securities- TipRanks. All rights reserved.
Sat, 07 May 2022 03:31 GMT Argenx Se (ARGX) Receives a Buy from Robert W. Baird- TipRanks. All rights reserved.
Fri, 06 May 2022 12:51 GMT Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX) and US Physical Therapy (USPH)- TipRanks. All rights reserved.
Tue, 22 Mar 2022 14:35 GMT Argenx Se (ARGX) Gets a Buy Rating from JMP Securities- TipRanks. All rights reserved.
Thu, 20 Jan 2022 15:45 GMT Argenx Se (ARGX) Receives a Buy from JMP Securities- TipRanks. All rights reserved.
Sun, 09 Jan 2022 02:15 GMT Argenx Se (ARGX) Receives a Buy from Kepler Capital- TipRanks. All rights reserved.
Fri, 07 Jan 2022 18:15 GMT Argenx Se (ARGX) Received its Third Buy in a Row- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.